These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

99 related items for PubMed ID: 6141493

  • 1. The comparison between enkephalin-like and dynorphin-like immunoreactivity in both monkey and human globus pallidus and substantia nigra.
    Haber SN, Watson SJ.
    Life Sci; 1983; 33 Suppl 1():33-6. PubMed ID: 6141493
    [Abstract] [Full Text] [Related]

  • 2. Possible interactions between dynorphin and dopaminergic systems in rat basal ganglia and substantia nigra.
    Quirion R, Gaudreau P, Martel JC, St-Pierre S, Zamir N.
    Brain Res; 1985 Apr 08; 331(2):358-62. PubMed ID: 2859094
    [Abstract] [Full Text] [Related]

  • 3. The distribution of dynorphinergic terminals in striatal target regions in comparison to the distribution of substance P-containing and enkephalinergic terminals in monkeys and humans.
    Reiner A, Medina L, Haber SN.
    Neuroscience; 1999 Apr 08; 88(3):775-93. PubMed ID: 10363817
    [Abstract] [Full Text] [Related]

  • 4. Met-enkephalin-like and dynorphin-like immunoreactivities of the basal ganglia of the cat.
    Chesselet MF, Graybiel AM.
    Life Sci; 1983 Apr 08; 33 Suppl 1():37-40. PubMed ID: 6141495
    [Abstract] [Full Text] [Related]

  • 5. Peptides derived from prodynorphin are decreased in basal ganglia of Huntington's disease brains.
    Dawbarn D, Zamir N, Waters CM, Hunt SP, Emson PC, Brownstein MJ.
    Brain Res; 1986 Apr 30; 372(1):155-8. PubMed ID: 2871898
    [Abstract] [Full Text] [Related]

  • 6. Correlation between Met-enkephalin and substance P immunoreactivity in the primate globus pallidus.
    Haber S, Elde R.
    Neuroscience; 1981 Apr 30; 6(7):1291-7. PubMed ID: 6167897
    [No Abstract] [Full Text] [Related]

  • 7. Opioid peptides in Huntington's disease: alterations in prodynorphin and proenkephalin system.
    Seizinger BR, Liebisch DC, Kish SJ, Arendt RM, Hornykiewicz O, Herz A.
    Brain Res; 1986 Jul 23; 378(2):405-8. PubMed ID: 2873872
    [Abstract] [Full Text] [Related]

  • 8. Primate model of Parkinson's disease: alterations in multiple opioid systems in the basal ganglia.
    Zamir N, Skofitsch G, Bannon MJ, Helke CJ, Kopin IJ, Jacobowitz DM.
    Brain Res; 1984 Nov 26; 322(2):356-60. PubMed ID: 6150750
    [Abstract] [Full Text] [Related]

  • 9. Light and electron microscopic localization of immunoreactive Leu-enkephalin in the monkey basal ganglia.
    DiFiglia M, Aronin N, Martin JB.
    J Neurosci; 1982 Mar 26; 2(3):303-20. PubMed ID: 6121017
    [No Abstract] [Full Text] [Related]

  • 10. Changes in dynorphin, enkephalin and cholecystokinin content of hippocampus and substantia nigra after amygdala kindling.
    Iadarola MJ, Shin C, McNamara JO, Yang HY.
    Brain Res; 1986 Feb 12; 365(1):185-91. PubMed ID: 2868784
    [Abstract] [Full Text] [Related]

  • 11. Corticotropin-releasing factor stimulates the release of methionine-enkephalin and dynorphin from the neostriatum and globus pallidus of the rat: in vitro and in vivo studies.
    Sirinathsinghji DJ, Nikolarakis KE, Herz A.
    Brain Res; 1989 Jun 26; 490(2):276-91. PubMed ID: 2569903
    [Abstract] [Full Text] [Related]

  • 12. [Active peptides in substance P preparations from cortex, globus pallidus and substantia nigra of human brains].
    Baldauf J, Harnacke P, Zetler G.
    Naunyn Schmiedebergs Arch Exp Pathol Pharmakol; 1968 Jun 26; 260(2):231-41. PubMed ID: 4239251
    [No Abstract] [Full Text] [Related]

  • 13. Steady state levels of pro-dynorphin-related end products in the striatum and substantia nigra of the adult rhesus monkey.
    Dores RM, Akil H.
    Peptides; 1985 Jun 26; 6 Suppl 2():143-8. PubMed ID: 2867528
    [Abstract] [Full Text] [Related]

  • 14. Immunohistochemical localization of dynorphin (1-8) in hypothalamic magnocellular neurons: evidence for absence of proenkephalin.
    Weber E, Roth KA, Evans CJ, Chang JK, Barchas JD.
    Life Sci; 1985 Jun 26; 31(16-17):1761-4. PubMed ID: 6130434
    [Abstract] [Full Text] [Related]

  • 15. Differential metabolism of dynorphins in substantia nigra, striatum, and hippocampus.
    Sandin J, Tan-No K, Kasakov L, Nylander I, Winter A, Silberring J, Terenius L.
    Peptides; 1997 Jun 26; 18(7):949-56. PubMed ID: 9357051
    [Abstract] [Full Text] [Related]

  • 16. Anterior to posterior variations in the concentration of somatostatin-like immunoreactivity in human basal ganglia.
    Davies P, Josef J, Thompson A.
    Brain Res Bull; 1981 Oct 26; 7(4):365-8. PubMed ID: 6117352
    [Abstract] [Full Text] [Related]

  • 17. Opiate receptor agonists as modulators of gamma-aminobutyric acid turnover in the nucleus caudatus, globus pallidus and substantia nigra of the rat.
    Moroni F, Cheney DL, Peralta E, Costa E.
    J Pharmacol Exp Ther; 1978 Dec 26; 207(3):870-7. PubMed ID: 215744
    [Abstract] [Full Text] [Related]

  • 18. Vesicular localization of immunoreactive [Met5]enkephalin in the globus pallidus.
    Coulter HD.
    Proc Natl Acad Sci U S A; 1988 Sep 26; 85(18):7028-32. PubMed ID: 3413134
    [Abstract] [Full Text] [Related]

  • 19. Immunocytochemical studies of substance P and Met-enkephalin in the basal ganglia and substantia nigra in Huntington's, Parkinson's and Alzheimer's diseases.
    Grafe MR, Forno LS, Eng LF.
    J Neuropathol Exp Neurol; 1985 Jan 26; 44(1):47-59. PubMed ID: 2578185
    [Abstract] [Full Text] [Related]

  • 20. The distribution of some identified peptide-containing pathways in the central nervous system including the basal ganglia.
    Zimmerman EA.
    Prog Clin Biol Res; 1981 Jan 26; 68():117-25. PubMed ID: 6272328
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 5.